APLI:CC News and Press, Appili Therapeutics Inc. From 03/28/25

The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (...

2025-03-24 09:45:00 ET Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta’s capabilities in early cancer risk assessment, complemen...

Acquisition is key to Pearsanta’s mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA/CAP-certified monitoring center and laboratories ...

2025-03-18 09:20:00 ET Aditxt (NASDAQ: ADTX) through its wholly owned subsidiary Adivir, Inc., is progressing with its planned acquisition of Appili Therapeutics (TSX: APLI; OTCPink: APLIF) under a court-approved plan of arrangement. Appili shareholders have overwhelmingly approved the ...

Four new funding proposals, totalling US$117.5 million, have been submitted for review Modifications received to U.S. Air Force Academy Cooperative Agreement Outside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIR...

2025-03-17 11:44:14 ET Aditxt (NASDAQ: ADTX) , a health innovation platform, provided a corporate update highlighting progress across its subsidiaries and acquisition initiatives. The company remains focused on advancing its autoimmune treatment subsidiary Adimune , precision diagnostic...

2025-03-06 08:50:00 ET Aditxt (NASDAQ: ADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person Syndrome. Adimune has completed preclinical s...

2025-02-21 09:32:11 ET Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO), expected in the second half of 2025. The IPO aims to support Pearsanta’s commercializa...

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission Further strengthened government partnerships, re...

Highland Copper Company Inc. (HI:CA) is expected to report for Q2 2025 WildBrain Ltd. Common and Variable Voting Shares (WILD:CA) is expected to report $0.01 for Q2 2025 GoldMoney Inc. (XAU:CA) is expected to report for Q3 2025 New Gold Inc. (NGD:CA) is expected to report $0.08 for Q4...